TLSA

Tiziana Life Sciences Ltd

TLSA, USA

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

https://www.tizianalifesciences.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TLSA
stock
TLSA

Tiziana Life Sciences CEO Increases Stake with Significant Share Purchase TipRanks

Read more →
TLSA
stock
TLSA

TLSA CEO Bolsters Stake with New Share Acquisition GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-03-31)

Rating:

BUY

Target Price:

$8.0682

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very High

24.67

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-183.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-63.89 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.87

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 3.91% of the total shares of Tiziana Life Sciences Ltd

1.

Dauntless Investment Group, LLC

(2.9257%)

since

2025/06/30

2.

Citadel Advisors Llc

(0.1703%)

since

2025/06/30

3.

HSBC Holdings PLC

(0.0902%)

since

2025/06/30

4.

Zhang Financial LLC

(0.0768%)

since

2025/06/30

5.

Susquehanna International Group, LLP

(0.0737%)

since

2025/06/30

6.

HRT FINANCIAL LLC

(0.072%)

since

2025/06/30

7.

Kovitz Investment Group Partners, LLC

(0.0679%)

since

2025/06/30

8.

Geode Capital Management, LLC

(0.0669%)

since

2025/06/30

9.

Fidelity Nasdaq Composite Index

(0.0669%)

since

2025/07/31

10.

Morgan Stanley - Brokerage Accounts

(0.0627%)

since

2025/06/30

11.

SIMPLEX TRADING, LLC

(0.0576%)

since

2025/06/30

12.

EWA, LLC

(0.0403%)

since

2025/06/30

13.

LPL Financial Corp

(0.0224%)

since

2025/06/30

14.

Jane Street Group LLC

(0.0214%)

since

2025/06/30

15.

Marshall Wace Asset Management Ltd

(0.0209%)

since

2025/06/30

16.

CI Private Wealth LLC

(0.0174%)

since

2025/06/30

17.

TWO SIGMA SECURITIES, LLC

(0.0149%)

since

2025/06/30

18.

Advisor Group Holdings, Inc.

(0.0131%)

since

2025/06/30

19.

Jnba Financial Advisors Inc

(0.0103%)

since

2025/06/30

20.

CapTrust Financial Advisors

(0.0094%)

since

2025/06/30

21.

Wealth Alliance, LLC

(0.0088%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-0.07

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-03-31)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(4.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.